Big week for China economic data; in the US, analyst conference season begins.» Read More
CNBC looks at those busy casino carpets and the surprising thing that is under them.
A lackluster year for the stock market has turned into a strong one for active fund managers.
The key is to look at the dollar move in the context of a longer-term trend, strategists told CNBC.
Former Wall Street financier Chris Andersen has spent a lifetime raising money on Wall Street. Now he's raising pigs.
Wall Street experts who blamed the economic slowdown this year on the brutal winter weather are being left out in the cold.
What happened to retail? It looks sluggish, despite a lot of noise.
Another market disruption from higher interest rates is virtually certain, according to former Federal Reserve Chairman Alan Greenspan.
Brazil is hardly a consensus target for international cash, but some are willing to be brave in spite of recent problems.
Total U.S. government debt holdings by the 18 largest banks in the country declined by $2.6 billion in the first quarter.
The worst of the Chinese slowdown is likely still ahead because of the nation's debt, according to a senior Morgan Stanley investment strategist.
Global bond yields are again rising, roiling stock markets in Europe and the United States.
With Nymex rebounding 40 percent since its lows of the year, many are asking if the uptrend will stay or whether if it is a short-term bounce.
Earnings in the second quarter will not be the same as the first, but analysts don't believe it.
Despite numerous Wall Street proclamations that its demise is near, investors refuse to buy into the notion that the bond bull market is dead.
Consumers seem to be spending money on cars, student loans, electronics and dining, but not on retail in general.
Stocks pop after jobs data
S&P futures moved almost 10 points on the April nonfarm payroll report of 223,000, essentially in line with expectations of 224,000.
Is Biotech topping out?
The hedge fund manager who has already made a killing betting against biotech company MannKind now says the stock will soon be worthless.
The Securities and Exchange Commission approved a long-awaited program to trade small cap stocks in increments of five cents, rather than a penny.